Hypertension antiplatelet therapy

Multiple-risk-factor intervention (treatment of dyslipidemia and hypertension, smoking cessation, antiplatelet therapy) reduces macrovascular events. 

The APT 1994 overview thus established conclusively the value of antiplatelet therapy for a wide range of patients at high risk of occlusive arterial disease. The proportional reductions in vascular events were shown to be similar in men and women, in middle age and old age, in hypertensive and normotensive patients, and in diabetic and non-diabetic patients (8). 

Kuriyama S, Tomonari H, Hosoya T. Antiplatelet therapy decreases the incidence of erythropoietin-induced hypertension in predialysis patients. Clin Exp Hypertens 1999 21(3) 213-22. 

First-line therapy of CAD depends on modification of risk factors such as smoking, hypertension (see Chapter 11), hyperlipidemia (see Chapter 35), obesity, and clinical depression. In addition, antiplatelet drugs (see Chapter 34) are very important. 

Active major bleeding, concurrent heparin therapy, thrombocytopenia associated with positive in vitro test for antiplatelet antibody, hypersensitivity to heparin or pork products Cautions Conditions with increased risk of hemorrhage, history of heparin-induced thrombocytopenia, impaired renal function, elderly uncontrolled arterial hypertension, history of recent GI ulceration and hemorrhage... 

---